|Jerry Mendell, MD|
|In 2004, Jerry Mendell, MD, was awarded the S. Mouchly Small Scientific Achievement Award from the Muscular Dystrophy Association, recognizing researchers who make significant contributions to neuromuscular disease research.|
in the news
Wellstone Center Designation
Groundbreaking. Multidisciplinary. Comprehensive. These words don’t just describe our world-class Neuromuscular Disorders program. They are fundamental to our work and the commitment we make to the families who come to us from across the country.
Our program not only offers leading specialists from key disciplines, we also coordinate patient care across each specialty. Patients benefit from coordinated care ranging from specialists in Neurology, Cardiology, Pulmonary Medicine and Endocrinology—all with expertise in pediatric neuromuscular disorders. But that’s only part of the story.
Nationwide Children’s hospital is a recognized leader in managing the treatments and outcomes of neuromuscular patients, but we’re also one of only a few institutions in the country actively working on a cure. Learn about Neuromuscular Disorders Clinical Research Studies.
Neuromuscular Disorders utilizes a multidisciplinary team to work specifically with children suffering from disorders such as muscular dystrophy, myositis and congenital myopathy, neuropathies and myasthenic disorders, among others. Our range of services includes:
We hope this web site helps you learn more about Neuromuscular Disorders and Nationwide Children's Hospital. On our site you can:
View a comprehensive list of the conditions and symptoms we treat
Meet the Neuromuscular Disorders Team
Find out about our Neuromuscular Disorders Clinic
Learn about numerous Neuromuscular Disorders Clinical Research Studies
Hosted by Kevin Flanigan, MD, "This Month in Muscular Dystrophy" podcasts highlight the latest in muscular dystrophy and other inherited neuromuscular disease research. During each podcast, authors of recent publications discuss how their work improves our understanding of inherited neuromuscular diseases, and what their work might mean for treatment of these diseases.
MDA and AVI BioPharma opened a phase-two trial of the exon-skipping drug eteplirsen on Aug. 15, 2011, at Nationwide Children's Hospital. Learn more about this ground-breaking clinical trial.